Neurology Central

Ocrelizumab approved for treatment of primary progressive multiple sclerosis

A license for the drug OCREVUS® (ocrelizumab) has been granted by the European Commission for use in patients with primary progressive multiple sclerosis (PPMS) and the more common relapsing-remitting form (RRMS). Previously, no treatments have been approved for PPMS, the most debilitating type of the disease.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.